U.S. flag An official website of the United States government
  1. Home
  2. Medical Devices
  3. Medical Device Safety
  4. Safety Communications
  5. UPDATE: Use of Renuvion/J-Plasma Device for Certain Aesthetic Procedures: FDA Safety Communication
  1. Safety Communications

UPDATE: Use of Renuvion/J-Plasma Device for Certain Aesthetic Procedures: FDA Safety Communication

Español

Date Issued: May 10, 2023

The U.S. Food and Drug Administration (FDA) is providing another update on the Renuvion/J-Plasma device system by Apyx Medical regarding use of the device for certain aesthetic skin procedures and an additional FDA clearance for a Renuvion/J-Plasma handpiece. The FDA recommends that health care providers be aware of the current indications and instructions for use for the Renuvion/J-Plasma system and handpieces.

  • In March 2022, the FDA warned against the use of Renuvion/J-Plasma for procedures intended to improve the appearance of the skin through dermal resurfacing (a procedure on the skin to treat wrinkles) or skin contraction (a procedure under the skin that can be performed either alone or in combination with liposuction to achieve skin effects, such as “tightening”). At that time, the Renuvion/J-Plasma device system was FDA cleared for general use of cutting, coagulation, and ablation of soft tissue during open and laparoscopic surgical procedures. The use of the device had not been determined to be safe or effective for any aesthetic skin procedures (procedures intended to improve the appearance of the skin).
  • In June 2022, we informed consumers and health care providers about the FDA clearance of a new handpiece for the Renuvion/J-Plasma device system that can be used for certain dermal resurfacing procedures. On May 25, 2022, the FDA cleared the Renuvion Dermal Handpiece for the treatment of moderate to severe wrinkles and rhytides, limited to patients with Fitzpatrick Skin Types I, II or III. This new handpiece is separate from Renuvion/J-Plasma handpieces that are cleared for general use of cutting, coagulation, and ablation of soft tissue during open and laparoscopic surgical procedures.
  • In July 2022, we informed consumers and health care providers about the FDA clearance of a Renuvion/J-Plasma handpiece that can be used under the skin in certain procedures intended to improve the appearance of loose skin. On July 15, 2022, the FDA cleared the Renuvion APR Handpiece for use in subcutaneous dermatological and aesthetic procedures to improve the appearance of lax (loose) skin in the neck and submental (under the chin) region. 

Today, we are informing consumers and health care providers about an additional FDA clearance for a Renuvion/J-Plasma handpiece that can be used under the skin in certain procedures intended to improve the appearance of the skin. On April 27, 2023, the FDA cleared the Renuvion APR handpiece for coagulation of subcutaneous soft tissues following liposuction for aesthetic body contouring.  The labeling and training for the Renuvion APR Handpiece will include detailed instructions for use and important safety information specific to this intended use.

Recommendations for Consumers

  • Discuss the benefits and risks of all available aesthetic skin procedures (procedures intended to improve the appearance of the skin) with your health care provider.
  • If you are considering any aesthetic skin procedure, ask which devices your provider will use during the procedure.

Recommendations for Health Care Providers

  • Discuss the benefits and risks of all available aesthetic skin procedures with your patient. If you are performing an aesthetic procedure, inform your patient which devices you plan to use.
  • Read and carefully follow the Instructions for Use (IFU) and training for the Renuvion/J-Plasma system and handpieces, as these include important safety information.
  • Be aware of the current indications for the Renuvion APR Handpiece:  
    • The Renuvion APR Handpiece is intended for the delivery of radiofrequency energy and/or helium plasma where coagulation/contraction of soft tissue is needed. Soft tissue includes subcutaneous tissue. 
    • The Renuvion APR Handpiece is intended for the coagulation of subcutaneous soft tissues following liposuction for aesthetic body contouring. 
    • The Renuvion APR Handpiece is indicated for use in subcutaneous dermatological and aesthetic procedures to improve the appearance of lax (loose) skin in the neck and submental region. 
    • The Renuvion APR Handpiece is intended for the delivery of radiofrequency energy and/or helium plasma for cutting, coagulation and ablation of soft tissue during open surgical procedures.
    • The Renuvion APR Handpiece is intended to be used with compatible electrosurgical generators owned by Apyx Medical.
  • Be aware that a separate handpiece, the Renuvion Dermal Handpiece, is indicated for the treatment of moderate to severe wrinkles and rhytides in patients with Fitzpatrick Skin Types I, II, or III.

Device Description

The Renuvion/J-Plasma system by Apyx Medical is a medical device that includes a handpiece and plasma generator. The system uses radiofrequency (RF) energy and helium to generate plasma (gas-like substance with high heat). 

FDA Actions

The FDA will continue to work with the manufacturer to monitor reports of adverse events for Renuvion/J-Plasma. The FDA will also continue to monitor reports of adverse events for other minimally invasive soft tissue heating devices in aesthetic skin procedures, and work to ensure that consumers and health care providers are informed about the intended uses of these devices.

The FDA will keep the public informed if any significant new information becomes available.

Reporting Problems with Your Device

If you think you had a problem with your device, the FDA encourages you to report the problem through the MedWatch Voluntary Reporting Form.

Health care personnel employed by facilities that are subject to the FDA's user facility reporting requirements should follow the reporting procedures established by their facilities.

Questions?

If you have questions, email the Division of Industry and Consumer Education (DICE) at [email protected] or call 800-638-2041 or 301-796-7100.

Back to Top